

Letter from the Editor

Jaume Capdevila

To view enhanced content go to www.rarecancers-open.com
Received: November 21, 2013 / Published online: November 28, 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Dear Colleague,

It is a real honor and pleasure for me to welcome you to *Rare Cancers and Therapy*. This new journal represents an international effort to focus on research and evidence-based medicine in rare neoplasms. *Rare Cancers and Therapy* is an international peer-reviewed, fully open access journal with a rapid publication policy that focuses on all topics related to low frequent and/or orphan tumors. Original research, outstanding reviews, case reports, and short communications in the different areas of knowledge of rare tumors are welcome, including molecular biology, basic, preclinical and translational research, epidemiology, diagnosis, healthcare economics, and

J. Capdevila (✉)
Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
e-mail: jacapdevila@vhebron.net



Enhanced content for this article is available on the journal web site: www.rarecancers-open.com

treatment options based on a multidisciplinary team approach and especially in new targeted agents and personalized medicine.

The management of rare neoplasms is a real challenge for physicians who need to deal with them. In the literature there are no peer-reviewed journals focused exclusively in the publication of all kind of scientific communications related to rare tumors. Original research and, even more importantly, referral reviews and specific case reports of rare cancers management are distributed through all available journals making it even more complicated to make diagnosis and treatment decisions in patients with rare neoplasms. One of the main purposes of this new journal is to join research and key opinion leaders' reviews in rare tumors giving health care professionals a new and easy accessible tool to gain enough knowledge to offer the best clinical practice in the different settings of rare cancers.

In addition to classic manuscript publication, *Rare Cancers and Therapy* will offer a range of additional features designed to increase visibility and readership. As such, each paper is accompanied by a bulleted slide summary giving a time-efficient overview of the

content to a wider readership. All submissions have the option to include slide sets, video components, animations, and/or interactive case studies.

I expect that the launching of *Rare Cancers and Therapy* will fill the lack of an “exclusive space” for all rare neoplasms in currently available journals and will give the scientific community the opportunity to join all available data on these tumors in a unique tool, facilitating physician’s daily clinical practice. I really encourage all health care professionals involved in the management of rare tumor patients to join this initiative and reach the

objective to create a referral journal for rare cancers and related therapies.

Jaume Capdevila

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.